Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue: +41.2%
EPS: −3.67%
Free cash flow: +79.0%

Quarter to September 2026, against a year earlier

161.45 1.69 +1.06%

Follow NBIX

Alert me

Market cap: $16.2B
P/E: 23.0×
Fwd P/E: 20.6×
Dividend yield: —
F-score: 7/9
Altman Z: 7.80
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Neurocrine Biosciences, Inc. 10-Q filed Jul 31, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Jul 31, 2026 · accepted 9:22 PM ET · Document on sec.gov · Filing index

Red flags

Inventory outpacing revenue Jul 31, 2026
Inventory grew 83.1% while revenue grew 39.5% year over year

10-Q filed Jul 31, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2025: 33 added · 24 removed · 15 modified; 4 with only figures updated

Neurocrine Biosciences, Inc. 10-Q filed Jul 31, 2026

Red flags

What changed

Stockrow Weekly